Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of Volixibat in Healthy Males
NCT02571192Phase 1Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Oct 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volixibat in Nonalcoholic steatohepatitis (NASH), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoints: Pharmacokinetic parameters (Cmax, AUC, tmax, t1/2, CL/F, Vz/F), Total radioactivity in whole blood and plasma and 1 more. Started Oct 2015; status: completed.
02
Drugs
volixibat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02571192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571192.